These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36714265)

  • 1. Pattern of autologous stem cell transplants at a tertiary care government hospital, with emphasis on transplant outcomes with pre-harvest CD34+ level.
    Dolai TK; De R; Sen A; Baul SN; Mitra S; Bhattacharya S; Mondal I; Mukhopadhyay K; Chattopadhyay A; Dutta S; Mandal PK
    Blood Cell Ther; 2022 Feb; 5(1):16-26. PubMed ID: 36714265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plerixafor and granulocyte colony stimulating factor for poor mobilizers in patients undergoing autologous peripheral hematopoietic stem cell transplantation: Single institution study.
    El Cheikh J; Terro K; El Warrak S; Ghaoui N; Sharrouf L; Timonian MA; Ismail F; Zahreddine A; Kreidieh N; Moukalled N; Abou Dalle I; Bazarbachi A
    Front Transplant; 2022; 1():1017579. PubMed ID: 38994380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.
    Yadav N; Mirgh SP; Aggarwal M; Agrawal N; Mehta P; Khushoo V; Kapoor J; Bhatia N; Agrawal P; Ahmed R; Bhurani D
    Indian J Cancer; 2023; 60(3):316-324. PubMed ID: 37787191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Liang EC; Muffly LS; Shiraz P; Shizuru JA; Johnston L; Arai S; Frank MJ; Weng WK; Lowsky R; Rezvani A; Meyer EH; Negrin R; Miklos DB; Sidana S
    Transplant Cell Ther; 2021 May; 27(5):405.e1-405.e6. PubMed ID: 33775587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of autologous transplant with non-cryopreserved peripheral blood stem cells in myeloma and lymphoma in Algeria. 10 years' experience.
    Bekadja MA; Entasoltan B; Amani K; Ouldjeriouat H; Osmani S; Bouchama S; Charef L; Arabi A; Brahimi M; Bouhass AR; Yafour N
    Tunis Med; 2022 Novembre; 100(11):762-768. PubMed ID: 37551517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
    Yang C; Dehghani M; Hopman W; Bhella S
    J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
    Elayan MM; Horowitz JG; Magraner JM; Shaughnessy PJ; Bachier C
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
    Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
    Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
    Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
    Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
    Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
    Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
    Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone.
    Voog E; Le QH; Philip I; Benetaib B; Michallet M; Fiere D; Thomas X
    Ann Hematol; 2001 Oct; 80(10):584-91. PubMed ID: 11732869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.
    Aggarwal V; Sabry W; Elemary M; Bosch M; Danyluk P; Mondal P; Stakiw J
    Curr Oncol; 2021 Apr; 28(3):1571-1580. PubMed ID: 33922026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study.
    Steiner N; Göbel G; Mauser L; Mühlnikel L; Fischinger M; Künz T; Willenbacher W; Hetzenauer G; Rudzki J; Nussbaumer W; Mayer W; Gunsilius E; Kircher B; Wolf D; Nachbaur D
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is neutropenic fever an obstacle to effective stem cell harvesting?
    Başcı S; Bozan E; Yaman S; Ulu BU; Bakırtaş M; Yiğenoğlu TN; Kılınç A; Özcan N; Dal MS; Çakar MK; Altuntaş F
    Asian J Transfus Sci; 2024; 18(1):21-26. PubMed ID: 39036677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation (ASCT) outcome for multiple myeloma in a tertiary referral centre in Malaysia.
    Liam CCK; Boo YL; Lee YL; Law KB; Ho KW; Shahnaz SAKS; Tan JTC; Lau NS; Ong TC; Tan SM; Sathar J
    Blood Cell Ther; 2021 Feb; 4(1):1-8. PubMed ID: 36712843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simplified method for autologous stem cell transplantation in multiple myeloma.
    Bekadja MA; Brahimi M; Osmani S; Arabi A; Bouhass R; Yafour N; Entasoltan B; Rasheed W; Attaf F
    Hematol Oncol Stem Cell Ther; 2012; 5(1):49-53. PubMed ID: 22446610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India.
    Garg V; Kodan P; Pushpam D; Bakhshi S; Kumar L; Sharma A; Gupta G; Gupta N
    Transfus Med; 2021 Oct; 31(5):377-382. PubMed ID: 34396610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation.
    Makhani SS; Oza SP; Reich-Slotky R; Munshi PN; Biran N; Donato ML; Siegel DS; Vesole DH; Naam S; Rowley SD
    Transplant Cell Ther; 2022 Jun; 28(6):306.e1-306.e7. PubMed ID: 35248777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.